Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Phase 2

Terminated

Conditions: Drug-Resistant Epilepsy
Focal-Onset Seizures

Interventions: Drug: Padsevonil

Registration Number: NCT03370120

Lead Sponsor: UCB Biopharma SRL

Brief Summary: The purpose of the study is to evaluate the long-term safety and tolerability of Padsevonil administered at individualized doses as adjunctive treatment for subjects with drug-resistant epilepsy.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 406

Inclusion Criteria

Subject is an adult (18 years of age or more )
Subject with epilepsy who has completed 1 of the previous Padsevonil (PSL) studies which allow access to the present study
Female subjects of child bearing potential must have a serum negative pregnancy test at the Entry Visit, which is confirmed to be negative by urine testing prior to further dispensing at each study visit thereafter. Subjects will be withdrawn from the study as soon as pregnancy is known. Female subjects will use an efficient form of contraception for the duration of the study and for a period of 3 months after their final dose of PSL.

Exclusion Criteria

Subject has any severe medical, neurological, or psychiatric condition, or laboratory value which may have an impact on the safety of the subject
Subject has active suicidal ideation as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the 'Since Last Visit' version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
Subject has >2x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total bilirubin (>= l.5x ULN total bilirubin if known Gilbert's syndrome) at the Entry Visit
Subject has a clinically-significant abnormality on electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
Subject has an abnormality on echocardiogram at last echocardiogram assessment, or foreseen in parent study as assessed by central reader that is accompanied by clinical symptoms or a Grade 2* (or higher)/moderate severity abnormality, or a history of rheumatic heart disease, or other known valvular abnormalities (*according to the ASE Guidelines, 2017; Zoghbi et al 2017)
Female subject who plans to be pregnant or is breastfeeding

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Padsevonil	Padsevonil	Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study. Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Participant and/or Caregiver or Observed by the Investigator During the Entire Study	From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)	An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal	From Entry Visit (Week 0) until the Safety Follow-up Visit (up to approximately 2 years)	An Adverse Event is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event that was not present prior to the initiation of the first dose of study treatment in this study or any unresolved event already present before initiation of the first dose that worsens in intensity following exposure to the treatment.
Change From Baseline (From the Respective Parent Study [EP0091 or EP0092]) in Observable Focal-onset Seizure Frequency Over the Evaluation Period	From Baseline in respective parent study over the Evaluation Period (up to approximately 2 years) in this study	Seizure frequency refers to 28-day adjusted frequency. Observable focal-onset seizures refer to Type IAl, IB, and IC (according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981). Focal-onset seizures include all Type I seizures.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (156): Ep0093 839
🇺🇸
Chandler, Arizona, United States
Ep0093 815
🇺🇸
La Jolla, California, United States
Ep0093 801
🇺🇸
San Francisco, California, United States
Ep0093 803
🇺🇸
Honolulu, Hawaii, United States
Ep0093 638
🇺🇸
Fort Wayne, Indiana, United States
Ep0093 707
🇺🇸
Lexington, Kentucky, United States
Ep0093 822
🇺🇸
Baltimore, Maryland, United States
Ep0093 818
🇺🇸
Bethesda, Maryland, United States
Ep0093 889
🇺🇸
Boston, Massachusetts, United States
Ep0093 645
🇺🇸
Golden Valley, Minnesota, United States
Scroll for more (146 remaining)
Ep0093 839
🇺🇸Chandler, Arizona, United States